Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Auteur de référence en rhumatologie
22 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (2 thèses dirigées)
Référence presse grand public
Cité 2 fois dans les médias — pédagogie reconnue
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Origine de la résistance à la vancomycine à partir des bactéries anaérobies strictes du tube digestifs? De Tn1549 à l'opéron vancd de Clostridium difficile
2009Doctorant·e : Krassimira Tsvetkova
Resistance aux aminosides par activation de genes cryptiques chez des bacteries a gram negatif
2001Doctorant·e : SOPHIE MAGNET
Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
53
53 articles ont été cités au moins 53fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
10 305
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
334
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
136
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Université Paris-Saclay · Assistance Publique – Hôpitaux de Paris · Bicêtre Hospital
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Il n'y a pas de propriété industrielle « verte »
2024ArticleRecueil Dalloz
Vente en ligne et réseaux de distribution : une liberté des distributeurs (encore) à conquérir
2024ArticleRecueil Dalloz
Thermal design criteria computation using various statistical approaches – application to a SFR fuel element
2024ArticleNuclear Engineering and Design
Le juge administratif et les garanties du contribuable vérifié
2023Chapitre
De l'impôt du contribubale à la contribution du citoyen
2023Chapitre
L'impossible preuve de la licéité de la distribution sélective quantitative
2023ArticleRecueil Dalloz
Enseigner le droit fiscal dans une faculté de droit et de sciences politiques
2023ArticleRevue européenne et internationale de droit fiscal
Le contrat d'assistance et de fourniture conforté par le droit bancaire
2022ArticleRecueil Dalloz
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Le Cheval.fr · 01/09/2023
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxNN3hObnhQOV95dE5EMER2ZjZaY2VUTkp4TFJuaTVnQ3FFMGw0aTB3eHV5d3pSVzdHMVg0V3Z3TVRWdDloZ0x0QjVkcG5LMzVBdjIwREdTMnVvMmNPWXU5N2h6SFBYb1RRaHpJYkV1Nld0UTNTMVdTZC1FOHVkMGRUUVJnQQ?oc=5" target="_blank">Gilles Siauve rejoint le Team Royal Horse</a> <fo
📰 Ouest-France · 10/12/2012
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNdm8yUXRFVjdvU2FvZHBibFNsNERDTVNYMDNNcU4tT0hsem95M0stNkkxcHh2eXlXVElhUElRUjVLSEExSVpmbGpDSjdaNFotclVaS1RFdFpsai12WWJMSHh1c2lrZnIwdEZmeVRtV3AyWGlxNWgxVVhyX0FGMGoxMENsU1lsZlJ6RXB6SkZLeWNwaWZabDYta0gtVkpxUW1NcGNQd0ZpSWhjem8?oc=5" target="_bla
Genome biology and evolution · 2014
Therapeutic advances in hematology · 2018
Haemophilia A and haemophilia B are congenital X-linked bleeding disorders caused by deficiency of coagulation factor VIII (FVIII) and IX (FIX), respectively. The preferred treatment option for patients with haemophilia is replacement therapy. For patients with severe disease, prophylactic replacement of coagulation factor is the treatment of choice; this has been shown to reduce arthropathy significantly, reduce the frequency of bleeds and improve patients’ quality of life. Prophylaxis with standard recombinant factor requires regular intravenous infusion at least two (FIX) to three (FVIII) times a week. Recombinant FVIII and FIX products with an extended half-life are in development, or have been recently licensed. With reported mean half-life extensions of 1.5–1.8 times that of standard products for FVIII and 3–5 times that of standard products for FIX, these products have the potential to address many of the unmet needs of patients currently treated with standard factor concentrates. For example, they may encourage patients to switch from on-demand treatment to prophylaxis and improve the quality of life of patients receiving prophylaxis. Indeed, extended half-life products have the potential to reduce the burden of frequent intravenous injections, reducing the need for central venous lines in children, promote adherence, improve outcomes, potentially allow for more active lifestyles and, depending on the dosing regimen, increase factor trough levels. Members of the Zürich Haemophilia Forum convened for their 19th meeting to discuss the practicalities of incorporating new treatments into the management of people with haemophilia. This review of extended half-life products considers their introduction in haemophilia treatment, including the appropriate dose and schedule of infusions, laboratory monitoring, patient selection, safety considerations, and the economic aspects of care.
Thrombosis and haemostasis · 2015
SummaryInhibitor development represents the most serious side effect of haemophilia treatment. Any difference in risk of inhibitor formation depending on the product used might be of clinical relevance. It was this study’s objective to assess inhibitor development according to clotting factor concentrate in severe haemophilia A and B. The European Haemophilia Safety Surveillance (EUHASS) was set up as a study monitoring adverse events overall and according to concentrate. Since October 2008, inhibitors were reported at least quarterly. Number of treated patients was reported annually, specifying the number of patients completing 50 exposure days (Previously Untreated Patients, PUPs) without inhibitor development. Cumulative incidence, incidence rates and 95 % confidence intervals (CI) were calculated. Data from October 1, 2008 to December 31, 2012 were analysed for 68 centres that validated their data. Inhibitors developed in 108/417 (26 %; CI 22–30 %) PUPs with severe haemophilia A and 5/72 (7 %; CI 2–16%) PUPs with severe haemophilia B. For Previously Treated Patients (PTPs), 26 inhibitors developed in 17,667 treatment years [0.15/100 treatment years; CI 0.10–0.22) for severe haemophilia A and 1/2836 (0.04/100; (CI 0.00–0.20) for severe haemophilia B. Differences between plasma-derived and recombinant concentrates, or among the different recombinant FVIII concentrates were investigated. In conclusion, while confirming the expected rates of inhibitors in PUPs and PTPs, no class or brand related differences were observed.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Blood advances · 2022 · Journal Article
Kruse-Jarres R, Peyvandi F, Oldenburg J, Chang T, et al.
Haemophilia : the official journal of the World Federation of Hemophilia · 2021 · Journal Article
Jiménez-Yuste V, Auerswald G, Benson G, Dolan G, et al.
Haemophilia : the official journal of the World Federation of Hemophilia · 2019 · Letter
Perrier-Cornet A, Philippe A, Lambert T, d'Oiron R, et al.
European journal of epidemiology · 2019 · Journal Article
Doncarli A, Demiguel V, Guseva Canu I, Goulet V, et al.
Therapeutic advances in hematology · 2018 · Journal Article
Lambert T, Benson G, Dolan G, Hermans C, et al.
Thrombosis research · 2014 · Journal Article
Lambert T, Auerswald G, Benson G, Hedner U, et al.
AIDS (London, England) · 2014 · Case Reports
Rivoisy C, D'Oiron R, Cherin M, Ségéral O, et al.
Infection control and hospital epidemiology · 2014 · Letter
Mizrahi A, Lambert T, Vidal B, Couzigou C, et al.
Hematology (Amsterdam, Netherlands) · 2012 · Journal Article
Auerswald G, Šalek SZ, Benson G, Elezović I, et al.
Research and practice in thrombosis and haemostasis · 2025 · Journal Article
Fischer K, Lassila R, Peyvandi F, Gatt A, et al.
Research and practice in thrombosis and haemostasis · 2024 · Journal Article
Fischer K, Lassila R, Peyvandi F, Gatt A, et al.
Thrombosis and haemostasis · 2020 · Clinical Trial, Phase III
Thrombosis and haemostasis · 2020 · Clinical Trial, Phase III
Kenet G, Chambost H, Male C, Halimeh S, et al.
Journal of thrombosis and haemostasis : JTH · 2019 · Clinical Trial, Phase II
Djambas Khayat C, El Khorassani M, Lambert T, Gay V, et al.
Haemophilia : the official journal of the World Federation of Hemophilia · 2025 · Journal Article
Fischer K, Lassila R, Peyvandi F, Gatt A, et al.
Research and practice in thrombosis and haemostasis · 2025 · Journal Article
Fischer K, Lassila R, Peyvandi F, Gatt A, et al.
Haemophilia : the official journal of the World Federation of Hemophilia · 2022 · Journal Article
Tardy B, Lambert T, Chamouni P, Montmartin A, et al.
Orthopaedics & traumatology, surgery & research : OTSR · 2015 · Journal Article
Thès A, Molina V, Lambert T
Genome biology and evolution · 2014 · Journal Article
Touchon M, Cury J, Yoon EJ, Krizova L, et al.
Clinical medicine insights. Arthritis and musculoskeletal disorders · 2019 · Journal Article
Bronstone A, Neary JT, Lambert TH, Dasa V
Additional file 6: Figure S2. of Comparative genomics of Clostridium bolteae and Clostridium clostridioforme reveals species-specific genomic properties and numerous putative antibiotic resistance determinants
Schematic view of operons coding for glycopeptides antibiotic resistance. Canonical organisation and CDSs present in genomes of C. bolteae and C. clostridioforme were shown. Percent sequence identity and percent positive
Additional file 3: Table S3. of Comparative genomics of Clostridium bolteae and Clostridium clostridioforme reveals species-specific genomic properties and numerous putative antibiotic resistance determinants
Overview of the flagellar locus found in C. clostridioforme. (XLSX 13 kb)
Additional file 5: Figure S1. of Comparative genomics of Clostridium bolteae and Clostridium clostridioforme reveals species-specific genomic properties and numerous putative antibiotic resistance determinants
Distance based phylogenetic tree of genes coding for butyrate kinase (buk). (PNG 721 kb)
Additional file 1: Table S1. of Comparative genomics of Clostridium bolteae and Clostridium clostridioforme reveals species-specific genomic properties and numerous putative antibiotic resistance determinants
Lactose operons of C.bolteae and C. clostridioforme. (XLSX 10 kb)
Comparative genomics of Clostridium bolteae and Clostridium clostridioforme reveals species-specific genomic properties and numerous putative antibiotic resistance determinants
Abstract Background Clostridium bolteae and Clostridium clostridioforme, previously included in the complex C. clostridioforme in the group Clostridium XIVa, remain difficult to distinguish by phenotypic methods. These b
Additional file 1: Table S1. of Comparative genomics of Clostridium bolteae and Clostridium clostridioforme reveals species-specific genomic properties and numerous putative antibiotic resistance determinants
Lactose operons of C.bolteae and C. clostridioforme. (XLSX 10 kb)
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Kenet G, Chambost H, Male C, Halimeh S, et al.
Clinical medicine insights. Arthritis and musculoskeletal disorders · 2019 · Journal Article
Bronstone A, Neary JT, Lambert TH, Dasa V
Journal of thrombosis and haemostasis : JTH · 2019 · Clinical Trial, Phase II
Djambas Khayat C, El Khorassani M, Lambert T, Gay V, et al.
Transfusion · 2017 · Clinical Trial
Lambert T, Rothschild C, Volot F, Borel-Derlon A, et al.
Thrombosis and haemostasis · 2015 · Journal Article
Fischer K, Lassila R, Peyvandi F, Calizzani G, et al.
European journal of haematology · 2017 · Journal Article
Hermans C, Auerswald G, Benson G, Dolan G, et al.
Thrombosis and haemostasis · 2016 · Clinical Trial, Phase III
Kenet G, Chambost H, Male C, Lambert T, et al.